TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Ű¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.

NEWS


NEWS

¹øÈ£ Á¦ ¸ñ ÷ºÎ ÀÛ¼ºÀÏ
301     [°øÁö] ȨÆäÀÌÁö ¾÷µ¥ÀÌÆ® – Epigenetics (ChIP-seq, CUT&RUN-seq) µ¥ÀÌÅÍ, °í°´ ÀÎÅÍºä ¿ÀÇ   2019.06.28
302     [½ÅÁ¦Ç°] Ç÷¾×, ¼Òº¯ µî »ýü»ùÇÿë direct qRT-PCR Mix Ãâ½Ã   2019.06.26
303     [°øÁö] ÀÓ½ÃÈÞ¹« (6/3) ¾È³»   2019.05.30
304     [½ÅÁ¦Ç°] UNG°¡ Æ÷ÇÔµÈ qPCR premix Ãâ½Ã (Dual-Labeled Probe °ËÃâ¹ý)   2019.05.28
305     [°øÁö] Human iPSC¸¦ »ç¿ëÇÑ ´Ù³¶¼º°£ÁúȯÀÇ in-vitro Áúº´ ¸ðµ¨ Á¦ÀÛÀÚ ÀÎÅÍºä   2019.05.15
306     [°øÁö] 5¿ù 8ÀÏ ¾÷¹« Á¶±âÁ¾·á ¾È³» (¿ÀÈÄ 4½Ã±îÁö)   2019.05.08
307     [°øÁö] ±Ù·ÎÀÚÀÇ ³¯(5/1) Á¤»ó±Ù¹« ¹× ÀÓ½ÃÈÞ¹«(5/3) ¾È³»   2019.05.01
308     [°øÁö] ȨÆäÀÌÁö ¾÷µ¥ÀÌÆ® – Epigenetics ¼±Åð¡À̵å, ChIP-seq ¿À¹öºä ÆäÀÌÁö ¿ÀÇ   2019.04.26
309     [°øÁö] ȨÆäÀÌÁö ¸Þ´º ½Å¼³ ¾È³» - Product index   2019.04.26
310     [°øÁö] Â÷¼¼´ë Áٱ⼼Æ÷ ¹è¾ç¹èÁö, DEF-CS¢â 500 Culture SystemÀÇ »ç¿ëÀÚ Èıâ È®ÀÎ   2019.04.15
311     [°øÁö] ½Å±Ô È«º¸ÀÚ·á Ãâ°£ – ÈļºÀ¯ÀüÇÐ (Epigenetics)À» À§ÇÑ ¸ðµç °Í   2019.04.11
312     [À̺¥Æ®] CRISPR/Cas9 ¼³¹®Á¶»ç À̺¥Æ® – 2Â÷ ¼±¹° ¹ß¼Û ¾È³» ¹× °¨»ç ÀÎ»ç   2019.04.05
313     [°øÁö] ȨÆäÀÌÁö ¾÷µ¥ÀÌÆ® - Next Generation Sequencing (NGS) : Upstream & Downstream ¾È³»   2019.04.05
314     [°øÁö] ȨÆäÀÌÁö ¾÷µ¥ÀÌÆ® – CRISPR Genome Editing ¿À¹öºä ÆäÀÌÁö °³Æí, ´Ù¾çÇÑ ÀÚ·á ¼ö·Ï   2019.03.27
315     [°øÁö] ȨÆäÀÌÁö ¾÷µ¥ÀÌÆ® - Cell-free Nucleic Acid NGS Ãßõ°¡ÀÌµå ¿ÀÇ   2019.03.26
    16  17  18  19  20  21  22  23  24  25  26  27  28  29  30